LKFT Stock — Price, Charts & Analysis

Lakefront Biotherapeutics NV (LKFT) has a trailing P/E of 2.71x and a forward P/E of -20.49x. This places LKFT in a lower earnings multiple territory based on the valuation data currently available on Worldtickers.

LKFT trades with 2.71x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether LKFT looks overvalued or undervalued.

LKFT's P/E of 2.71x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

LKFT's trailing EPS is $10.45 and forward EPS is -$1.38.

EPS, or earnings per share, shows how much profit Lakefront Biotherapeutics NV generated for each share. LKFT's trailing EPS is $10.45, and investors usually prefer EPS that is positive and growing over time.

Lakefront Biotherapeutics NV has a market cap of $1.85B, making LKFT a small-cap stock based on the current market value shown on Worldtickers.

LKFT's latest stock price on Worldtickers is $28.30. The latest move is -$1.06 or -3.61%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

LKFT's quote includes a latest price of $28.30. The market open is $29.11. Previous close is $29.36. The intraday range is $28.26 to $29.11.

LKFT is down in the latest quote, with a move of -$1.06 or -3.61%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

LKFT generated $990.57M in trailing revenue. Revenue growth is -81.50%, which helps show whether demand is expanding or slowing.

LKFT's revenue growth is -81.50%, which is a negative demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, LKFT shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is $594.32M.

Gross margin is 67.61%. Margins show how efficiently Lakefront Biotherapeutics NV turns revenue into profit.

Lakefront Biotherapeutics NV carries $6.36M and holds $2.24B in cash.

LKFT holds $2.24B on its balance sheet.

LKFT's book value per share is $2.86.

Institutions hold 23.64% of LKFT shares. Insiders hold 25.45% of shares. Ownership mix helps investors understand how much of Lakefront Biotherapeutics NV is held by professional investors and company insiders.

LKFT has 65.48M shares outstanding. Float shares are 486.05M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for LKFT, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for LKFT is -$1.38. Revenue growth is -81.50%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

LKFT's trailing EPS is $10.45. Forward EPS is -$1.38. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

LKFT is in the Healthcare sector. Its earnings multiple is 2.71x. Its latest displayed growth metric is -81.50%. Compare these figures with sector peers before deciding whether Lakefront Biotherapeutics NV is stronger or weaker than average.

LKFT trades at $28.30. The stock trades at 2.71x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Lakefront Biotherapeutics NV's fundamentals.

LKFT risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.11, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

LKFT should be compared with companies in Biotechnology. Its earnings multiple is 2.71x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Lakefront Biotherapeutics NV (LKFT) operates in Healthcare, specifically Biotechnology. Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, cu

LKFT trades on NasdaqGS. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

LKFT stock is priced in USD on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Lakefront Biotherapeutics NV's official website listed on Worldtickers is lakefrontbio.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Lakefront Biotherapeutics NV employs about 452 people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Lakefront Biotherapeutics NV is headquartered in Mechelen, Belgium. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

LKFT is in the Healthcare sector and the Biotechnology industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

LKFT has traded between $25.68 and $37.78 over the past 52 weeks. At $28.30, it is 25.09% below the high and 10.20% above the low. The 52-week range helps gauge long-term price momentum.

LKFT is below both its 50-day and 200-day moving averages, which is a common downtrend signal. Its 50-day moving average is $28.64 and its 200-day moving average is $30.54.

LKFT's RSI is 52.17. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

LKFT's latest RSI reading is 52.17, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for LKFT is near $25.68. Key resistance is near $29.91. Breaks above resistance or below support can change the short-term technical setup.

LKFT's nearest reported support level is $25.68. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

LKFT's nearest reported resistance level is $29.91. A breakout above resistance can improve momentum, especially when volume confirms the move.

LKFT trades about 201.69K shares daily on average. The latest displayed volume is 204.27K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

LKFT's MACD is 0.24, which is a positive momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

LKFT is below both its 50-day and 200-day moving averages, which is a common downtrend signal. RSI is 52.17 (neutral). MACD is bullish. Nearest support is around $25.68. Resistance is around $29.91. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is $27.54 (2.76% from price). MA50 is $28.64 (-1.19% from price). MA200 is $30.54 (-7.32% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. LKFT's MA20 is $27.54. MA50 is $28.64. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

LKFT's pivot is near $29.31. Support is near $25.68. Resistance is near $29.91. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for LKFT is near $27.21. The next upper resistance zone is near $29.47. These levels help define risk and possible follow-through zones after a breakout or breakdown.

LKFT's Bollinger range is roughly $25.96 to $29.12. Band width is near 11.45%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

LKFT's ATR-based typical daily range is about 2.85%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 204.27K shares. Average volume is about 201.69K shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

LKFT's all-time high shown on Worldtickers is $274.03. Its all-time low is $12.91. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

LKFT has a beta of 0.11, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.